On September 12, 2023, ROME Therapeutics, Inc. closed the transaction. The company has amended the terms of the transaction. The company raised $72,000,005 in its second and final tranche.

The company raised $149,000,000 in the transaction. The tranche included participation from new investors Johnson & Johnson Innovation - JJDC, Inc., Bristol-Myers Squibb Company, Eurofarma Ventures, Mirae Asset Capital Co,Ltd., Investment Arm, Raycap Inc., Luma Group, Sigmas Group and all the existing investors. The round was oversubscribed.